Histopathological Downstaging of Colon Cancer Following Six Weeks of Pre-operative Chemotherapy: Early Results of the NCRI FOxTROT Trial by West, N, Tinkler-Hundal, E, Handley, K, Magill, L, Lancaster, D, Seymour, M, Ferry, D, Warren, B, Brown, G, Gray, R, Morton, D, Quirke, P

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer by Gray, R, Morton, D, Brown, G, Ferry, DR, Magill, L, Quirke, P, Seymour, M, Warren, B, Grp, F

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report by Morton, D, Magill, L, Handley, K, Brown, G, Ferry, DR, Gray, Z, Quirke, P, Seymour, M, Warren, B, Gray, R, Grp, F

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial by West, N, Hemmings, G, Richman, S, Taylor, M, Chambers, P, Magill, L, Lancaster, D, Taniere, P, Handley, K, Brown, G, Ferry, D, Seymour, M, Gray, R, Morton, D, Warren, B, Quirke, P

Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience. by Dighe, S, Swift, I, Magill, L, Handley, K, Gray, R, Quirke, P, Morton, D, Seymour, M, Warren, B, Brown, G

“… AIM: A pilot study was undertaken to determine the accuracy of computed tomography (CT) staging in identifying patients with high-risk colon cancers who would be considered as candidates for a neoadjuvant therapy trial (FOxTROT) and those at low risk (T1/T2) who would be excluded. …”